Opinion|Videos|March 4, 2024

An Overview of the SPOTLIGHT Trial for PSMA PET in Prostate Cancer

Author(s)Brian Helfand, MD, PhD, Brian Chapin, MD, Sean P. Collins, MD, PhD

A panel of experts introduce the SPOTLIGHT study, evaluating PSMA PET in patients with prostate cancer.

Episodes in this series

EP. 1 The Evolution of Imaging Techniques in Prostate Cancer

EP. 1 The Evolution of Imaging Techniques in Prostate Cancer

EP. 2 The Utility of PSMA PET in Prostate Cancer

EP. 2 The Utility of PSMA PET in Prostate Cancer

EP. 3 Clinical Development of PSMA-Targeted Therapies

EP. 3 Clinical Development of PSMA-Targeted Therapies

EP. 4 Clinical Practices of PSMA-Targeted Agents in Prostate Cancer

EP. 4 Clinical Practices of PSMA-Targeted Agents in Prostate Cancer

EP. 5 Multidisciplinary Approaches in PSMA PET for Prostate Cancer

EP. 5 Multidisciplinary Approaches in PSMA PET for Prostate Cancer

EP. 6 Patient Profile 1: A 51-Year-Old Man with High-Risk Localized Prostate Cancer

EP. 7 PSMA PET Imaging and Clinical Perspectives from Patient Profile 1

EP. 8 LIGHTHOUSE Trial and The Role of 18F-rhPSMA-7.3 for Staging of Prostate Cancer

EP. 8 LIGHTHOUSE Trial and The Role of 18F-rhPSMA-7.3 for Staging of Prostate Cancer

EP. 9 An Overview of the SPOTLIGHT Trial for PSMA PET in Prostate Cancer

EP. 9 An Overview of the SPOTLIGHT Trial for PSMA PET in Prostate Cancer

EP. 10 SPOTLIGHT Trial and 18F-rhPSMA-7.3 for Prostate Cancer

EP. 10 SPOTLIGHT Trial and 18F-rhPSMA-7.3 for Prostate Cancer

EP. 11 Patient Profile 2: A 62-Year-Old Man with Recurrent Prostate Cancer

EP. 12 Patient Profile 3: A 67-Year-Old Male with Recurrent Prostate Cancer

EP. 13 Future Horizons in PSMA-Targeted Imaging and the Management of Prostate Cancer

EP. 13 Future Horizons in PSMA-Targeted Imaging and the Management of Prostate Cancer

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

The role of diet and lifestyle in prostate cancer care, with Lorelei A. Mucci, ScD, MPH

ByLorelei A. Mucci, ScD, MPH

September 11th 2026

Doublet or triplet? Urologists weighs in on mCSPC options

ByUrology Times staff

September 10th 2026

Interpreting real-world evidence in ARPI treatment decisions, with Martin Schoen, MD, PhD

ByMartin Schoen, MD, PhD,Hannah Clarke

September 10th 2026

App-based intervention aims to increase PSA screening among Black men

ByHannah Clarke

September 9th 2026

The critical role of advocacy in urologic oncology

ByRuchika Talwar, MD,Lan Anh Galloway, MD

September 9th 2026

Latest CME

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

AI-generated profiles impersonate female urologists to market ED products online

The role of diet and lifestyle in prostate cancer care, with Lorelei A. Mucci, ScD, MPH

Doublet or triplet? Urologists weighs in on mCSPC options

John Sfakianos, MD, discusses evolving management of recurrent LG-IR-NMIBC

Alternative BCG strains may help address ongoing supply challenges in NMIBC